GlassScriptPhysician profile
Gregory P Spielbauer
NPI 1609843663
$1,012.02
in general payments reported to CMS, 2019-2025
15 companies · $691 in 2025
The $691 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $206.96 | 2019-2025 | Krystexxa, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $144.46 | 2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $142.39 | 2019-2025 | Airsupra |
| Pfizer INC. | $104.27 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.26 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $80.16 | 2019-2025 | Shingrix |
| Novo Nordisk INC | $53.30 | 2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $48.60 | 2019 | |
| Exact Sciences Corporation | $30.22 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $23.76 | 2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $22.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.09 | 2025 | Xifaxan |
| Vertex Pharmaceuticals Incorporated | $15.67 | 2025 | |
| Shire North American Group INC | $14.99 | 2019 | |
| Allergan, INC. | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Spielbauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.